Accentia Biopharma's sinusitis drug fails to meet main goal

(Reuters) - Accentia Biopharmaceuticals Inc said its potential treatment for chronic sinusitis failed to meet the main goal of a late-stage clinical trial.

The company said its lead product candidate, SinuNase, failed to achieve the required level of statistical significance as compared to placebo.

Accentia, which expects complete data on the drug in April, said it would analyze the data of both the primary and secondary goals to determine the next steps in advancing the product.

(Reporting by Esha Dey in Bangalore; Editing by Anil D'Silva)